Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI AG
2020-12-01
|
| 叢編: | Pharmaceuticals |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/1424-8247/13/12/470 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|